Biogen
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Benepali® PEN Patient Satisfaction Survey
- Conditions
- Rheumatoid ArthritisSpondyloarthropathies
- Interventions
- Biological: Benepali
- First Posted Date
- 2017-10-31
- Last Posted Date
- 2018-10-23
- Lead Sponsor
- Biogen
- Target Recruit Count
- 500
- Registration Number
- NCT03327454
- Locations
- 🇩🇪
Research Site, Ulm, Germany
A Drug Interaction Study of BIIB074 and an Oral Contraceptive Regimen
- Conditions
- Drug Interactions
- Interventions
- Drug: OC (ethinyl estradiol and levonorgestrel)
- First Posted Date
- 2017-10-30
- Last Posted Date
- 2018-09-25
- Lead Sponsor
- Biogen
- Target Recruit Count
- 36
- Registration Number
- NCT03324685
- Locations
- 🇺🇸
Research Site, Daytona Beach, Florida, United States
Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease
- First Posted Date
- 2017-10-24
- Last Posted Date
- 2022-02-28
- Lead Sponsor
- Biogen
- Target Recruit Count
- 357
- Registration Number
- NCT03318523
- Locations
- 🇬🇧
Royal Hallamshire Hospital, Sheffield, West Midlands, United Kingdom
🇺🇸University of Kansas Medical Center Research Institute, Kansas City, Kansas, United States
🇺🇸Cedars Sinai, Los Angeles, California, United States
A Study to Assess the Pharmacodynamic Effects of SAGE-217 in Healthy Adults Using an Insomnia Model
- Conditions
- Healthy
- Interventions
- Drug: SAGE-217 high doseDrug: SAGE-217 low doseDrug: Placebo
- First Posted Date
- 2017-09-15
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- Biogen
- Target Recruit Count
- 45
- Registration Number
- NCT03284931
- Locations
- 🇺🇸
Sage Investigational Site, New York, New York, United States
Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy
- Conditions
- Epilepsy, Focal Seizures, Partial Seizures
- Interventions
- Other: Placebo
- First Posted Date
- 2017-09-14
- Last Posted Date
- 2021-12-14
- Lead Sponsor
- Biogen
- Target Recruit Count
- 67
- Registration Number
- NCT03283371
- Locations
- 🇺🇸
Research Site, Renton, Washington, United States
Safety, Tolerability, and Pharmacokinetics of Single Doses of BIIB059 in Healthy Japanese Subjects.
- First Posted Date
- 2017-07-21
- Last Posted Date
- 2018-08-31
- Lead Sponsor
- Biogen
- Target Recruit Count
- 32
- Registration Number
- NCT03224793
- Locations
- 🇺🇸
West Coast Clinical Trials, Cypress, California, United States
Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS)
- Conditions
- Multiple Sclerosis
- Interventions
- Drug: PlaceboDrug: BIIB033 (opicinumab)
- First Posted Date
- 2017-07-19
- Last Posted Date
- 2022-04-28
- Lead Sponsor
- Biogen
- Target Recruit Count
- 263
- Registration Number
- NCT03222973
- Locations
- 🇬🇧
Research Site, Swansea, United Kingdom
Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy
- Conditions
- Relapsing Remitting Multiple Sclerosis
- Interventions
- First Posted Date
- 2017-06-06
- Last Posted Date
- 2020-11-25
- Lead Sponsor
- Biogen
- Target Recruit Count
- 80
- Registration Number
- NCT03177083
- Locations
- 🇵🇹
Hospital Fernando Fonseca, Amadora, Portugal
🇵🇹Hospital Evora, Evora, Portugal
🇵🇹Hospital de Braga, Braga, Portugal
A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using BIIB112
- Conditions
- X-Linked Retinitis Pigmentosa
- Interventions
- Biological: BIIB112
- First Posted Date
- 2017-04-14
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- Biogen
- Target Recruit Count
- 50
- Registration Number
- NCT03116113
- Locations
- 🇬🇧
Research Site, Southampton, United Kingdom
Observational Study to Evaluate the Real-Life Effectiveness of Benepali Following Transition From Enbrel
- Conditions
- Rheumatoid ArthritisAxial Spondyloarthritis
- Interventions
- Biological: BenepaliBiological: Enbrel
- First Posted Date
- 2017-04-04
- Last Posted Date
- 2021-02-05
- Lead Sponsor
- Biogen
- Target Recruit Count
- 585
- Registration Number
- NCT03100734
- Locations
- 🇩🇪
Research Site, München, Bavaria, Germany